CSL and University of Queensland revealed on Friday enough vaccine had already been made for phase three trials, for which the manufacturer is seeking regulatory approval before the end of this year.
Early data from phase one clinical trials shows the CSL-UQ vaccine is safe, well tolerated and induces a strong immune response, UQ’s Professor Paul Young said.
It has also been shown lower doses are just as effective, so the amount of vaccine being made will stretch further.
Health Minister Greg Hunt said that while the CSL-UQ version of the vaccine would not be available until late 2021, there would be other forms available by March to start vaccinating frontline health workers and others on the priority list.
Pfizer reported its candidate vaccine had a 90 per cent effectiveness rate in late-stage clinical trials.
Mr Hunt said the national goal was for all Australians who want to be vaccinated to have the shots by the end of next year.
Prime Minister Scott Morrison is meeting with state and territory leaders on Friday to discuss how to rollout the vaccines.
Mr Hunt said the strategy would involve making the vaccine available through hospitals, respiratory clinics, GPs and possibly special vaccine centres if the states agreed.
National cabinet is also considering the framework to reopen Australia by Christmas as infection rates plummet across the country.
Jump to next article